DBV Technologies (DBVT) Cash from Financing Activities (2020 - 2026)
DBV Technologies (DBVT) reported Cash from Financing Activities of $88.9 million for Q1 2026, down 44.11% quarter-over-quarter from $159.1 million in Q4 2025.
DBV Technologies (DBVT) Cash from Financing Activities (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has 7 years of Cash from Financing Activities data on file, last reported at $88.9 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $88.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $365.1 million (up 56153.0% YoY), and the FY2025 annual result was $276.2 million, up 46949.74% from the prior year.
- Cash from Financing Activities fell to $88.9 million in Q1 2026 per DBVT's latest filing, from $159.1 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $195.4 million in Q2 2022 and troughed at -$837000.0 in Q3 2023.
- A 5-year average of $35.4 million and a median of -$3500.0 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities sank 342.86% in 2024, then surged 354621.21% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at -$283000.0 in 2022, then soared by 33.22% to -$189000.0 in 2023, then surged by 457.14% to $675000.0 in 2024, then surged by 23464.44% to $159.1 million in 2025, then tumbled by 44.11% to $88.9 million in 2026.
- Business Quant data shows DBVT's Cash from Financing Activities at $88.9 million in Q1 2026, $159.1 million in Q4 2025, and $130000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn | 88.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 88.90 Mn |
| Mar 31, 2026 | 88.90 Mn |
| Dec 31, 2025 | 159.06 Mn |
| Dec 31, 2025 | 159.06 Mn |
| Sep 30, 2025 | 130,000.00 |
| Sep 30, 2025 | 130,000.00 |
| Jun 30, 2025 | 116.99 Mn |
| Jun 30, 2025 | 116.99 Mn |
| Dec 31, 2024 | 675,000.00 |
| Dec 31, 2024 | 675,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Jun 30, 2024 | -33,000.00 |
| Jun 30, 2024 | -33,000.00 |
| Mar 31, 2024 | -62,000.00 |
| Mar 31, 2024 | -62,000.00 |
| Dec 31, 2023 | -189,000.00 |
| Dec 31, 2023 | -189,000.00 |
| Sep 30, 2023 | -837,000.00 |
| Sep 30, 2023 | -837,000.00 |